10 High Growth Healthcare Stocks to Invest in Now

5. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Revenue Growth: 65.42% 

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is emerging as a high-growth healthcare stock with significant potential for investors.  It is a biopharmaceutical company that specializes in developing RNA interference (RNAi) therapeutics, a novel class of medicines based on Nobel Prize-winning science. The company focuses on creating treatments for rare and severe diseases, as well as more common conditions like high cholesterol.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) reported strong Q3 2024 financial results, with total product revenue reaching $420 million, a 34% year-over-year increase. Revenue from its TTR franchise totaled $309 million, also up by 34%, while the rare disease franchise generated $111 million, reflecting the same growth rate. The company’s revenue growth was primarily driven by rising patient demand for its marketed products, particularly within the TTR franchise.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is approaching 5,000 patients on treatment with ONPATTRO or AMVUTTRA globally for hATTR polyneuropathy. However, the company estimates that 25,000 to 30,000 patients worldwide suffer from this disease, indicating significant growth potential. The corporation is also preparing for a potential launch in ATTR cardiomyopathy, pending regulatory approval. This expansion could significantly increase Alnylam’s addressable market and drive future growth.

The company is advancing its pipeline with several key developments. It has completed regulatory submissions for vutrisiran in ATTR cardiomyopathy in both the U.S. and EU. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) also initiated a Phase 1 study for ALN-HTT02 targeting Huntington’s disease and reported promising results from a Phase 1 study of mivelsiran for early-onset Alzheimer’s disease. By the end of 2025, the corporation aims to file nine proprietary INDs and potentially 15 new INDs, including partnered programs, significantly expanding its clinical pipeline.

Street analysts have a consensus Moderate Buy rating for the stock, with an average 12-month price target of $313.81. The price target range varies from a low of $205.00 to a high of $400.00, suggesting a potential upside of 28.14% from the stock’s current price of $244.89.